ALLOGENIC EX VIVO EXPANDED NATURAL KILLER CELLS
Diffuse Large B-cell Lymphoma With no Other Specification
Emercell SASCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
270 Active assets in the Diffuse Large B-cell Lymphoma With no Other Specification cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
Axicabtagene Ciloleucel Ruijin Hospital | Phase 4 | BBB |
PREDNISONE TABLETS Beth Israel Deaconess Medical Center | Phase 4 | BBB |
Inno-206 Beth Israel Deaconess Medical Center | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →